A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus

COREOS Collaborators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)778-784
Number of pages7
JournalGastroenterology
Volume161
Issue number3
DOIs
StatePublished - Sep 2021

Funding

FundersFunder number
Novartis
Bristol-Myers Squibb
Bristol-Myers Squibb
Sanofi
Dr. Falk Pharma
Glaxo Smith Kline
Eli Lilly and Company
Reckitt Benckiser
Zealand Pharma
National Peanut Board
GlaxoSmithKline
Shire
Bayer
AstraZeneca
AstraZeneca
Shire/Takeda
UpToDate
Dr. Falk Pharma
Medtronic
Celgene
Nutricia, Norgine, SST
Receptos
Nestlé Nutrition Institute
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung32003B_160115/1, 32473B_185008
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung32003B_160115/1, 32473B_185008

    Keywords

    • Clinical Trials
    • End Points
    • Endoscopy
    • Eosinophilic Esophagitis
    • Histology
    • Histopathology
    • Outcomes
    • Patient-Reported Outcomes
    • Quality of Life
    • Symptoms

    Cite this